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ABSTRACT
The aim of the current study is to demonstrate normal and malignant
prostatic epithelial cells (PrECs) as targets for receptor-mediated estro-
genic and antiestrogenic action. Using an improved protocol, we have
successfully isolated and maintained highly enriched populations of nor-
mal PrECs from ultrasound-guided peripheral zone biopsies, individually
determined to be morphologically normal. Semiquantitative reverse tran-
scription-PCR analyses were used to determine whether transcripts of
estrogen receptor (ER)-a and those of ER-b were expressed in our normal
PrEC primary cultures, in a commercially available PrEC preparation
(PrEC; Clontech), in an immortalized PrEC line established from a
benign prostatic hyperplasia specimen (BPH-1), and in three prostatic
cancer cell lines (LNCaP, PC-3, and DU145). Expression levels of ER-a
and ER-b transcripts were related to those of two estrogen-responsive
genes [progesterone receptor (PR) and pS2], at the message levels, to gain
insights into the functionality of the ER subtypes in PrECs. Interestingly,
only transcripts of ER-b, but not those of ER-a, were found in our
primary cultures of normal PrECs, along with both PR and pS2 mRNA.
These data strongly suggest that estrogen action was signaled exclusively
via ER-b in normal human PrECs. In contrast, PrEC (Clontech) and
BPH-1 cells expressed both ER-a and ER-b transcripts and no PR nor
pS2 mRNA in PrEC and only a minimal level of PR mRNA in BPH-1.
Among the three prostate cancer cell lines, LNCaP expressed ER-b
mRNA along with transcripts of PR and pS2, DU145 expressed messages
of ER-b and PR, and PC-3 cells exhibited ER-a, ER-b, and pS2 mRNA.
Thus, unlike normal PrECs, expression patterns of these genes in malig-
nant PrECs are more variable.
Treatment of prostate cancer cells with demethylation agents effectively
reactivated the expression of ER-a mRNA in LNCaP and DU145 and that
of pS2 message in DU145. These findings provide experimental evidence
that ER-a gene silencing in prostate cancer cells, and perhaps also in
normal PrECs, are caused by DNA hypermethylation.
To evaluate the potential of using antiestrogens as prostate cancer
therapies, we have assessed the growth-inhibitory action of estrogens
(estradiol and diethylstilbestrol) and antiestrogens (4-hydroxy-tamoxifen
and ICI-182,780) on PC-3 and DU-145 cells. In PC-3 cells, which express
both ER subtypes, estrogens as well as antiestrogens are effective inhibi-
tors. In contrast, in DU145 cells, which express only ER-b, antiestrogens,
but not estrogens, are growth inhibitors. By comparison, ICI 182,780 is
the more effective cell growth inhibitor. Importantly, the ICI 182,780-
induced antiproliferative effects were reversed by cotreatment of DU145
cells with an ER-b antisense oligonucleotide, hence lending additional
support to a central role played by ER-b in mediating growth-inhibitory
action of antiestrogens.
INTRODUCTION
Charles Huggins pioneered the use of the synthetic estrogen, DES,4
in the treatment of advanced PCa in the early 1940s (1). The action of
DES was thought to be mediated via a blockade of the pituitary-
testicular axis, which effectively lowered circulating levels of andro-
gen and caused tumor regression (2). However, recent investigations
have demonstrated that DES exerts direct growth-inhibitory effects on
prostatic cancer cells via induction of mitotic arrest or apoptosis
(3–6). Unfortunately, because of serious adverse effects induced by
the estrogenicity of DES (feminization, exacerbation of heart failure,
vascular complications, gynecomastia, and impotence), the xenoestro-
gen has lost its attractiveness as a mainstay treatment for advanced
PCa (7). Clinical use of TAM, a nonsteroidal estrogen mixed agonist/
antagonist, was introduced in the 1980s as an alternative to DES in the
treatment of PCa. It was better tolerated than DES but only produced
low response rates (8–12). It was therefore concluded that further
investigation of TAM in advanced PCa treatment was not warranted.
Of late, two recent developments have rekindled interests in using
antiestrogens as therapeutics for PC: (a) pure estrogen antagonists
(e.g., ICI-164,384 and ICI-182,780; Ref. 13) and selective estrogen
receptor modulators, such as raloxifene (14), have become available
for clinical trials. Experimental evidence suggests that their mecha-
nisms of action may differ significantly from those of estrogens
(15–18) and therefore may yield more favorable outcomes; and (b) a
newly discovered ER subtype (ER-b) was found to be expressed at
high levels in the epithelial compartments of the rat prostate (19–23).
Although ER-b shares high homology with the classical ER (ER-a),
the two ER subtypes may regulate different sets of cellular functions
(18, 24). Recent findings from an ER-b knockout mouse suggest that
ER-b may suppress proliferation and prevent hyperplasia in the rodent
prostate (25). Taken together, these new findings raise an intriguing
possibility that ER-b is expressed in normal and/or malignant human
PrECs and plays a role in mediating estrogen action in these cell types.
Knowledge of the distribution of ER-b in normal and malignant
human PrECs is limited at this time. A recent study reported a lack of
ER-b expression in human prostate tissues (26), whereas several
preliminary reports noted expression of this receptor subtype in basal
epithelial cells of the human (27–29). In this study, we reported the
development of an effective method to obtain and culture “pure” or
highly enriched populations of normal PrECs from needle biopsies of
the peripheral zone of the human prostate. Expression levels of ER-a
and ER-b transcripts in our primary cultures of normal PrECs were
compared with those found in a PrEC preparation obtained from a
commercial source (PrEC; Clontech), in an immortalized PrEC cell
line established from a BPH specimen (BPH-1; Ref. 30), and in three
prostatic cancer cell lines (DU145, PC-3, and LNCaP). Expression
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levels of ER-a and ER-b in normal and malignant PrECs were then
related to the transcript expression levels of two estrogen-responsive
genes (PR and pS2) to gain insights into the functionality of the ER
subtypes. Additionally, we have compared the efficacy of two estro-
gens (DES and E2) to those of two antiestrogens (4OH-TAM and ICI)
in inhibiting cell growth in PC-3 and DU145 cells. An ER-b antisense
ODN was then used to demonstrate that the antiestrogen-induced
growth-inhibitory effects on prostate cancer cells were mediated via
an ER-b signaling mechanism. Finally, we provided the first experi-
mental evidence in support of DNA methylation-mediated transcrip-
tional inactivation of gene expression as the mechanism of ER-a
silencing in PrECs.
MATERIALS AND METHODS
Establishment of Normal PrECs in Primary Cultures. Tissue specimens
used for generating primary cultures of normal PrECs were obtained from
patients undergoing transrectal ultrasound-guided biopsies of the prostate for
standard clinical indications. All patients contributing biopsy material were
invited to participate in a prospective tissue acquisition study approved by the
local Institutional Review Board (approval was granted to J. L. at the New
England Medical Center). Written informed consent was obtained prior to
biopsy from participating patients. From each participant, one biopsy core was
obtained from the peripheral zone of the prostate, placed on a sponge pad
soaked in sterile saline; a 1–2-mm section was excised from the midportion of
the core and suspended in 5 ml of culture medium (described below). The two
remaining ends of the core were inked at the ends opposite the sectioned
midportion piece, placed in 10% formalin, and processed for histology. His-
tological examination of the end pieces of a biopsy core allowed us to
determine the histological nature and the homogeneity of the core. Only
specimens judged to be histologically normal, with no hyperplastic or neo-
plastic tissue contamination, were used to establish primary cultures of normal
PrECs.
Each harvested tissue specimen was then washed three times with HBSS
and cut into five to seven smaller pieces. The pieces were suspended in 2 ml
of freshly prepared growth medium (see below) and transferred to a 60-mm
Falcon culture dish (Becton Dickinson, Lincoln Park, NJ) coated with type I rat
tail collagen (Collaborative Biomedical Products, Bedford, MA). An epithelial
cell selection medium (the growth medium), reported previously (31), con-
sisted of keratinocyte serum-free medium with 25 mg/ml bovine pituitary
extract, 5 ng/ml epidermal growth factor, 2 mM L-glutamine, 10 mM HEPES
buffer, P/S (100 units/ml penicillin and 100 mg/ml streptomycin), 5.5 ml/ml
fungizone, 20 ng/ml cholera toxin, and 1% heat-inactivated FBS was used to
obtain enriched populations of PrECs. All culture reagents were obtained from
Life Technologies, Inc. (Grand Island, NY) except for FBS, which was
purchased from Sigma Chemical Co. (St. Louis, MO). The culture was incu-
bated at 37°C in a 5% CO2 atmosphere without disturbance for 7 days to allow
epithelial cells to grow out of the tissue pieces. Culture medium was then
routinely replaced every 4 days until cell culture reached ;80% confluence.
The cells were split once before they were used for RNA extraction.
In addition to primary cultures obtained from biopsy explants, a batch of
normal human PrECs were purchased from Clonetics Co. (San Diego, CA).
The PrEC cells were cultured in the PrEGM medium (Clontech) supplemented
with SingleQuots (Clonetics Co.) according to the manufacturer’s recom-
mended protocol.
Maintenance of Established Prostatic Cell Lines. All culture reagents
were obtained from Life Technologies and FCS from Sigma (St. Louis, MO),
except otherwise specified. BPH-1 (30), a nontumorigenic, SV40-immortal-
ized, highly differentiated human prostate epithelial cell line, was provided as
a gift by Dr. Simon Hayward at the University of California (San Francisco,
CA). This cell line was maintained in RPMI 1640 with 10 mM HEPES, 1 mM
sodium pyruvate, 2 mM L-glutamine, 4.5 g glucose/l, and 1.5 g of sodium
bicarbonate/L (American Type Culture Collection, Rockville, MD) plus 5%
heat-inactivated FBS, ITS (insulin-transferrin-selenium mixture; Collaborative
Biomedical Research, Bedford, MA), and P/S. Three human prostate cancer
cell lines (DU145, PC-3, and LNCaP) were purchased from American Type
Culture Collection. For routine maintenance, DU145 and PC-3 cells were
grown in DMEM/F-12 supplemented with heat-inactivated FBS, 2 mM
L-glutamine, 1 mM sodium pyruvate, 0.1 M nonessential amino acids, P/S, 0.05
mM b-mercaptoethanol (Sigma), and 1% ITS1. LNCaP cells were maintained
in the same medium used for BPH-1 except that ITS1 was left out from the
medium. All cell cultures were incubated at 37°C under a 5% CO2 atmosphere.
RNA Isolation and RT-PCR. Total cellular RNA was isolated using RNA
Stat-60 reagent (Tel-Test, Inc., Friendswood, TX) according to protocols
provided by the manufacturer. The quality of each total RNA sample was
checked and controlled by the following steps: (a) measurement of absorbance;
(b) running of a denaturing RNA gel capable of detecting possible RNA
degradation, as judged by the integrity and intensity of the 18S and the 28S
rRNA signals; and (c) conducting a semiquantitative RT-PCR for the 18S
rRNA at low cycle numbers. One mg of total cellular RNA was reverse
transcribed using the GeneAmp RNA PCR kit (Perkin-Elmer, Norwalk, CT),
and 2 ml of the resulting cDNA were used in each PCR.
Intron-spanning primers were either obtained from published literature or
designed using the Primer3 Output program.5 Primer sequences for GAPDH,
ER-a (primer set #1, exon 1–3), ER-b, PR, and AR are given in Table 1. All
PCR conditions were optimized for quantification of relative message contents
under nonsaturating conditions. Preliminary experiments were conducted to
ensure linearity for all semiquantitative procedures. Hot-start PCR using
AmpliTaq Gold DNA polymerase (Perkin-Elmer) was used in all amplification
reactions. The enzyme was activated by preheating the reaction mixtures at
95°C for 6 min prior to PCR. This protocol was chosen to minimize nonspe-
cific product amplification. The routine PCR program was 30 cycles of 1 min
at 94°C, 1 min at 60°C (annealing temperature), and 1 min at 72°C with the
following modifications: (a) amplification for ER-b cDNA used an annealing
temperature of 58°C; (b) amplifications of ER-a cDNA and AR cDNA were
carried out at an annealing temperature of 55°C; (c) cycle number for ER-a
cDNA amplification was set at 35; and (d) GAPDH cDNA was amplified at 26
cycles. GAPDH cDNA levels served as a loading control. Amplification of the
correct sequence was verified by direct DNA sequencing of each PCR product
from at least two different samples.
To further confirm that primary cultures of normal PrECs and certain
prostate cancer cell lines did not express ER-a mRNA (see “Results”), we used
two additional pairs of primers (primer sets #2 and #3, Table 1) to amplify
regions downstream of the coding sequence of ER-a (668 bp of exon 3–6 and
710 bp of exon 5–8, respectively). Together, these three pairs of pairs of ER-a
primers (Table 1) covered most of the length of the coding sequence. They had
been used successfully in our recent study on the expression of ER-a mRNA
in ovarian cancer (32). If PCR at high cycle number failed to yield products
from all three pairs of primers, we considered the sample to be devoid of ER-a
cDNA.
Treatment of DU145, PC-3, and LNCaP Cells with Demethylating
Agents. The three prostatic cancer cell lines were seeded at a density of 104
cells/ml medium in 25-cm2 culture flasks, allowed to attach during a 24-h
period, and exposed to two demethylating agents separately. The demethylat-
ing agents were added daily in aqueous solution. 59-Azacytidine was added at
final concentrations of 2.5 and 5 mM and 59-aza-29-deoxycytidine at 0.5 and
0.75 mM, respectively. Culture medium was changed every 4 days, and cells
were subjected to a total of 8 days of demethylating agent treatment. At the end
of the treatment period, the medium was removed, and cellular RNA was
extracted for RT-PCR.
Treatment of DU145 and PC-3 Cells with Estrogens/Antiestrogens.
Cells were seeded at a density of 5 3 103 per ml into 24-well plates (Falcon;
Becton Dickinson Labware, Lincoln Park, NJ) in a final volume of 1 ml of
culture medium with 5% charcoal-stripped FBS. Twenty-four h after seeding,
triplicate wells of cells were treated in with 1, 10, and 100 mM of E2, DES,
4OH-TAM, or ICI. E2, DES, and 4OH-TAM were purchased from Sigma, and
ICI was a generous gift from Zeneca Pharmaceuticals (Macclesfield, United
Kingdom). Estrogens and antiestrogens were dissolved in absolute ethanol
(Sigma) and added to the media daily. Cell cultures that were not treated with
estrogenic compounds received absolute ethanol as a vehicle control. Total
additive ethanol concentrations never exceeded 0.2% throughout the culture
period. The cells were refed with freshly prepared medium every other day. At
the end of a 4-day treatment period, cells in each well were trypsinized, and
5 Internet address: http://www.genome.wi.mit.edu/cgi-bin/primer/primer3.cgi.
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cell count was determined by direct counting using the trypan blue exclusion
method. All treatment experiments were repeated at least three times to
generate statistically relevant data.
Treatment of DU145 Cells with ICI and ER-b Antisense ODN. DU145
cells (5 3 103 cells/well) were plated in 24-well plates (Falcon; Becton
Dickinson Labware). After allowing 24 h for cell attachment, cell cultures
were treated in triplicate with 1 mM of ICI in the presence of 2.5 mM ER-b
antisense, sense, or mismatch ODNs for 4 days. The ER-b antisense ODN, an
18-mer, was designed to recognize the first translation start site on the ER-b
mRNA and its immediate 59 flanking region (Table 2). The nucleotide se-
quence of sense ODN is complementary to those of ER-b antisense ODN
(Table 2). On the basis of the sequence of ER-b antisense ODN, five nucle-
otides were scrambled to generate a mismatch ODN that retains the same GC
ratio of the ER-b antisense ODN (Table 2). Both the sense and the mismatch
ODNs served as controls for the antisense ODN. In all three ODNs, the first
and the last three nucleotides were phosphorothioate modified to increase their
stability in cellulo. The number of viable cells in each well was determined by
direct counting using the trypan blue exclusion method after a 4-day treatment
period. At least three individual experiments were performed to obtained
statistically relevant data.
Statistics. Statistical analysis was performed by using Student SYSTAT
software (Course Technology, Inc., Cambridge, MA). Data were analyzed by
one-way ANOVA, followed by the Tukey post-hoc test, and a 95% confidence
limit was used for all comparisons among treatment groups.
RESULTS
Expression of AR, ER-b, PR, and pS2 mRNA, but not ER-a
Transcripts, in Normal PrECs in Primary Cultures. Five primary
cultures of normal PrECs (N4#6, N3#5, N3#4, N2#3, and N2#2) were
established in our laboratory from ultrasound-guided peripheral zone
biopsies over a period of 18 months. The biopsy cores were all judged
upon histological examination to contain only normal prostatic tissue
with no BPH or cancerous foci contamination. The primary cell
cultures were all early passages (second or third), cobblestone in
appearance, with no visible fibroblast contamination. Semiquantita-
tive RT-PCR analyses (Fig. 1) demonstrated that our normal PrEC
cultures retained high levels of AR mRNA expression, which usually
disappeared in late-passage normal PrEC primary cultures or in es-
tablished PrECs (33). Interestingly, all five cultures of normal PrECs
expressed uniform levels of ER-b RNA and transcripts of the estro-
gen-responsive genes, PR and pS2. In contrast, expression of ER-a
mRNA was noticeably absent in all five cultures, even when high
cycle number PCR (.42 cycles) was used to amplify the cDNA.
Interestingly, PrEC (Clonetics Co.), a commercially prepared normal
PrEC culture, and BPH-1, a SV40 immortalized prostatic epithelial
cell line, expressed both ER-a and ER-b, but no PR or pS2 transcripts
in PrEC (Clontech), and only a minimal level of PR mRNA in BPH-1.
Expression of ER-b, ER-a PR, and pS2 mRNA in Prostatic
Cancer Cell Lines. All three prostatic cancer cell lines, DU145,
PC-3, and LNCaP, express ER-b mRNA (Fig. 1, a and c). In contrast,
ER-a mRNA was expressed only in the PC-3 cells. Interestingly, PR
transcripts were detected only in DU145 and LNCaP cells and not in
PC-3 cells. Messages of pS2 were found in PC-3 and LNCaP cells but
not in DU145 cells. In accordance with reports in the literature, AR
mRNA expression was only noted in LNCaP cells.
Expression of ER-a Variant in Prostate Cell Lines. When RT-
PCR analyses were conducted for ER-a mRNA semiquantification in
PrEC (Clonetics Co.), BPH-1, or PC-3 cells, we noticed that, in
addition to the expected PCR product, a smaller PCR product was
coamplified (Fig. 1, a and b). Sequencing analysis (data not shown)
revealed that this smaller PCR product was derived from an ER-a
mRNA variant that had the entire exon 2 deleted. We reported
recently the coexistence of this ER-a mRNA variant with wild-type
transcripts in normal and malignant human ovarian surface epithelial
cells (33).
Demethylation Reactivates ER-a and pS2 mRNA Expressions
in DU145 Cells and ER-a Expression in LNCaP Cells. Prior to
exposure to demethylating agents, ER-a and pS2 transcripts were not
detected in RNA samples prepared from DU145 cells (Fig. 1, a and c,
and Fig. 2). After the 8-day treatment with 59-aza-cytidine (2.5 and 5
mM) or 59-aza-29deoxycytidine (0.5 and 0.75 mM), DU145 cells re-
gained expression of both transcripts (Fig. 2). Interestingly, the ab-
sence of AR mRNA expression in DU145 cells was not reversed by
treatment with demethylating agents. Exposure of LNCaP cells to
demethylating agents also reactivated ER-a mRNA expression (data
not shown).
Effect of Antiestrogens and Estrogens on Cell Growth of DU145
and PC-3 Cells. Cell growth analyses showed that the growth of
DU145 cells, which only expressed ER-b mRNA, was adversely
effected by the antiestrogens ICI and 4OH-TAM (Fig. 3, A and B). A
dose-dependent inhibition of cell numbers was observed in cultures
exposed to ICI for 4 days when compared with control cultures treated
with vehicle (absolute ethanol). A 40% reduction (P , 0.001) in the
cell numbers was achieved with an ICI dose of 1 mM. A similar
Table 1 Primer sequences for the RT-PCR analysis
Target gene Primer sequence Location (nt)a Expected size
ER-b ERb-1: 59-TGA AAA GGA AGG TTA GTG GGA ACC-39 230–253 528 bp
ERb-2: 59-TGG TCA GGG ACA TCA TCA TGG-39 737–757
ER-a ERa-1: 59-TAC TGC ATC AGA TCC AAG GG-39 41–60 650 bp
ERa-2: 59-ATC AAT GGT GCA CTG GTT GG-39 671–690 (exon 1–3)
ERa-3: 59-GTG GGA ATG ATG AAA GGT GG-39 742–761 668 bp
ERa-4: 59-TCC AGA GAC TTC AGG GTG CT-39 1390–1409 (exon 3–6)
ERa-5: 59-GTG CCT GGC TAG AGA TCC TG-39 1142–1161 710 bp
ERa-6: 59-TGG TGC ATG ATG AGG GTA AA-39 1832–1851 (exon 5–8)
PR PR-1: 59-GAT TCA GAA GCC AGC CAG AG-39 1817–1836 533 bp
PR-2: 59-TGC CTC TCG CCT AGT TGA TT-39 2330–2349
pS2 pS2-1: 59-GGA GAA CAA GGT GAT CTG CG-39 52–71 236 bp
pS2-2: 59-CAC ACT CCT CTT CTG GAG GG-39 268–287
AR AR-1: 59-CTC TCT CAA GAG TTT GGA TGG CT-39 2896–2918 342 bp
AR-2: 59-CAC TTG CAC AGA GAT GAT CTC TGC-39 3214–3237
GAPDH GAPDH-F: 59-CCA CCC ATG GCA AAT TCC ATG GCA-39 152–175 598 bp
GAPDH-R: 59-TCT AGA CGG CAG GTC AGG TCC ACC-39 726–749
a
nt, nucleotide.
Table 2 Oligonucleotide sequences for the antisense ODN experiments
Target gene Sequences Locationa Size
ER-b
Antisense 59-Cb Ab Tb CAC AGC AGG GCT Ab Tb Ab-39 215 to 13 18 bp
Sense 59-Tb Ab Tb AGC CCT GCT GTG Ab Tb Gb-39
Mismatch 59-Gb Ab Tb CTC AGC ACG GCA Ab Ab Tb-39
a The first base of translation-initiating site is 11.
b This base was phosphorothioate modified.
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growth-inhibitory response was observed when DU145 cells were
treated with 4OH-TAM. However, cell number reduction achieved
with 1 mM 4OH-TAM was only ;25% (P , 0.001). In contrast,
exposure of DU145 cells to 1 mM estrogens (E2 and DES) did not
affect cell growth in 4-day exposure experiments (Fig. 3, C and D).
However, in a separate series of experiments, DU145 cells were
treated with 10 mM DES, and we observed a significant reduction in
cell number (data not shown). Furthermore, we had conducted com-
petition experiments to determine whether E2 could reverse the
growth-inhibitory effects induced by ICI and 4OH-TAM. DU145 cells
were treated with 1026 M ICI or 4OH-TAM in the absence or presence
of 1028, 1027, 1026 M E2. E2 at all three concentrations was unable
to reverse the ICI- or 4OH-TAM-induced cell growth inhibition (data
not shown).
When PC-3 cells, which expressed transcripts of both ER subtypes,
were exposed to antiestrogens (ICI and 4OH-TAM), a 25–30% reduction
in cell growth was noted in cultures treated with 1 or 10 mM of ICI or with
1 mM 4OH-TAM (P , 0.001; Fig. 4, A and B). Furthermore, exposure of
PC-3 cells to E2 at 1 or 10 mM concentrations also induced inhibition of
cell growth (P , 0.05 and P , 0.01, respectively; Fig. 4C). Interestingly,
treatment with DES at the various concentrations up to 1026 M did not
elicit statistically significant cell growth inhibition in PC-3 cells (Fig.
4D). However, in a separate experiment, PC-3 cells were treated with 10
mM DES, and we observed a significant reduction in cell number (data not
shown). Additionally, we had conducted competition experiments to
determine whether DES could reverse the growth-inhibitory effects in-
duced by ICI and 4OH-TAM. PC-3 cells were treated with 1026 M ICI or
4OH-TAM in the absence or presence of 1028, 1027, or 1026 M of DES.
DES was able to reverse the ICI-induced, but not 4OH-TAM-induced,
cell growth inhibition in a dose dependent manner (data not shown).
Reduction of ICI-induced Cell Growth Inhibition by ER-b
Antisense ODN. Treatment of DU145 cells were with ICI at 1 mM
induced a 40% reduction in cell number (Fig. 3). Cotreatment of
DU145 cells with ICI and an ER-b antisense ODN led to restoration
of cell number (P , 0.001; Fig. 5) whereas cotreatments with an
ER-b sense ODN or a mismatch ODN (Table 2) did not reverse the
ICI-induced effects. These data support the notion that the ICI-
Fig. 1. Results of RT-PCR analyses of ER-a, ER-b, PR, pS2, and AR mRNAs among normal and malignant prostatic epithelial cells. Total RNAs were extracted and reverse
transcribed. The resultant cDNAs were subjected to PCR analyses under optimized conditions. The amplified products were run into 2% agarose gel with ethidium bromide. Three
individual experiments were performed. a, representative fluorographs for ER-a, ER-b, PR, pS2, AR- and GAPDH RT-PCR analyses. b, an excerpt from the ER-a fluorograph, enlarged
to illustrate the exon 2 deletion variant of ER-a (ERaD2) in PC-3 cells. c, a summary of the data from RT-PCR analyses performed in three individual experiments. 1, detectable level
of expression; 2, undetectable level of expression.
Fig. 2. Reactivation of ER-a and pS2 mRNA expression in DU145 cells by de-
methylating agents. Cells were treated with either 2.5 mM (A1) or 5 mM (A2) 59-aza-
cytidine or 0.5 mM (D1) or 0.75 mM (D2) 29-deoxy-59-aza-cytidine for 8 days. Cells without
treatment were used as control (N). At the end of treatment, total RNAs were extracted
and subjected to RT-PCR analyses as described in Fig. 1.
3178
ESTROGEN RECEPTOR b IN PROSTATE CANCER
induced cell growth inhibition in DU145 cells is mediated via an
ER-b signaling mechanism.
DISCUSSION
The roles played by estrogens in the neoplastic transformation of
PrECs as well as in PCa progression and treatment remain controver-
sial. Exposure of humans or rodents to estrogens induces a prolifer-
ative lesion, squamous metaplasia, in their prostates (34–37), whereas
prolonged treatment of Noble rats with androgen plus estrogen causes
a high incidence of PCa in the dorsolateral prostates of the treated
animals (38–41). Paradoxically, DES, TAM, and other estrogens
have been used as treatment regimens for advanced metastatic PCa (1,
7–12, 42, 43). In addition to acting as chemical castration agents, both
estrogen and antiestrogen are believed to exert direct growth-inhibi-
tory effects on prostatic cancer cells via induction of apoptosis or cell
cycle arrest (3–6, 44). Precisely how estrogens/antiestrogens elicit
these actions remains uncertain.
Traditionally, the actions of estrogens/antiestrogens are thought to
be mediated via the classical ER, the a subtype, which has been
localized to the stromal compartment and basal epithelial cells of
human and rodent prostates (22, 26, 45–48). Because ER-a is not
expressed in the normal glandular epithelium of rat or human prostate
(4, 21, 26, 46–49), it is widely believed that the action of estrogen/
antiestrogen on normal PrECs is indirect, likely mediated via estro-
gen-induced stromal factors. However, after the discovery of ER-b
(19) and its localization to the epithelial compartment of rodent
prostates (19, 21, 50), a distinct possibility has been raised that
estrogen/antiestrogen could influence PrEC function via an ER-b
signaling pathway. However, at present, information on ER-b in
human PrECs is limited. Only one recent study (26) has evaluated the
expression pattern of ER-b transcripts and proteins in human prostatic
tissues and found nondetectable levels in both normal and diseased
tissues. In contrast, the present study unequivocally demonstrated
expression of ER-b mRNA in highly enriched or pure human PrEC
cultures established from peripheral zone biopsies. Furthermore, be-
cause ER-a message was undetectable but transcripts of two estrogen-
dependent genes, PR and pS2, were expressed in these cultures, these
data strongly suggest that ER-b is the cellular mediator of estrogen
action in normal human PrECs. Of interest to note is that both ER-a
and ER-b mRNA, but not PR or pS2 transcripts, were expressed
in a PrEC preparation purchased from a commercial source (PrEC;
Clontech) and in the immortalized PrEC line, BPH-1, with only a
minimal level of PR transcripts. The discrepancies between ER sub-
type, PR, and pS2 expression in our primary PrEC cultures and those
observed in PrEC (Clontech) and BPH-1 could be attributable to the
tissue of origin of these cell cultures/lines. In this regard, PrEC cultures
(Clontech) are routinely prepared from whole prostates, and BPH-1 was
derived from a benign hyperplastic specimen (30), whereas our primary
cultures were established from ultrasound-guided peripheral zone biop-
sies.
Issues relating to whether ER, and which subtype, is expressed in
cancerous PrECs remain unsettled. Several investigators (51, 52)
observed ER-a expression in human prostate cancer cell lines, includ-
ing LNCaP, PC-3, and DU-145, whereas others (53) did not. Simi-
larly, observations on ER-a expression in prostate cancer specimens
were equally controversial. Bonkhoff et al. (26) reported recently that
ER-a expression was infrequent in low-to-moderate grade adenocar-
cinoma but common in high-grade and metastatic cancers. Con-
versely, Konishi et al. (54) noted the presence of ER-a immuno-
positivity in well-differentiated adenocarcinomas but not in poorly
Fig. 3. Effects of antiestrogens and estrogens on cell growth of
DU145 cells. Cells (5 3 103 cells/well) were plated in triplicate
wells onto a 24-well plate. After 24 h for cell attachment, cells
were treated for 4 days with antiestrogens (A, ICI and B, 4OH-
TAM) or estrogens (C, E2 and D, DES) at various concentrations
as indicated. Cells treated with vehicle (absolute ethanol) were
used as control. The number of viable cells at the end of 4 days of
treatment was determined by the trypan blue exclusion method.
Three individual experiments were performed. Columns, means;
bars, SD; n 5 9; p, P , 0.001 compared with control (o).
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differentiated specimen. The latter observation was supported by two
additional studies that reported no ER-a expression in lymph node
and distant metastases (53, 55). These issues become more convoluted
when the expression pattern of ER-b is taken into consideration. A
lack of ER-b expression in human prostate tissues was reported by
Bonkhoff et al. (26), whereas several preliminary reports noted ex-
pression of this receptor subtype in dysplastic and cancerous tissues
(27–29). Findings in the present study revealed that ER-b mRNA was
expressed in all three cancer cell lines (PC-3, DU145, and LNCaP),
although in accordance with the literature, the ER-a message was only
detected in PC-3 cells (51). Unlike primary PrEC cultures, which
uniformly expressed both PR and pS2 transcripts, PR mRNA expres-
sion was only detected in DU145 and LNCaP cells whereas pS2
transcripts were found in PC-3 and LNCaP cells. Hence, despite
uniform expression of ER-b, the expression patterns of ER-a, PR, and
pS2 among these prostatic cancer cell lines was variable. Because
transcription of PR and pS2 is well recognized to be regulated by
estrogen (56–58), the loss of expression of these two genes in some
prostatic cancer cell lines suggests a deregulation of estrogen signal-
ing in these cells. A similar phenomenon has been observed in ovarian
cancer cell lines that express both ER subtype but no PR (33).
Until now, it remains unknown as to why prostatic epithelium
expresses only ER-b and not ER-a. In the present study, we demon-
strated that treatment of DU145 and LNCaP cells with demethylating
agents reactivated ER-a expression in these cells. These data provide
the first experimental evidence in support of DNA methylation-
mediated gene silencing (59, 60) as a mechanism of ER-a inactivation
in PrECs. In breast cancers, it had been shown that hypermethylation
of the promoter region of ER-a was associated with loss of expression
of this receptor subtype in hormone-refractory cancers (61–64). Be-
cause of the fragile nature of PrECs in primary culture, we had not
subjected them to demethylating agent treatment; it is reasonable to
assume that the same mechanism transcriptional inactivation operates
in ER-a silencing in the normal prostatic epithelium. Interestingly,
loss of pS2 expression in DU145 cells might also be linked to
hypermethylation-mediated transcriptional inactivation because expo-
sure of this cell line to demethylating agents revived pS2 expression.
Fig. 4. Effects of antiestrogens and estrogens on cell growth of
PC-3 cells. Cell growth assay was described in Fig. 3. A, ICI. B,
4OH-TAM. C, E2. D, DES. Columns, means; bars, SD; n 5 9; p,
P , 0.001; #, P , 0.01; 1, P , 0.05; compared with control (o).
Fig. 5. Reversal of ICI-induced DU145 cell growth inhibition by ER-b antisense ODN.
Cells were treated with ICI at 1026 M in the absence or presence of 2.5 mM of the
antisense, sense, or mismatch ODNs for 4 days. Cell numbers in “untreated” cultures
received no ICI treatment and were arbitrarily assigned a value of 100% (first column on
the left). Cell numbers in cultures treated with ICI and ICI plus ODNs were expressed as
percentages of cell numbers in the “untreated” cultures. Columns, means; bars, SD;
n 5 16. p, significant difference between ICI-treated cultures and those that received ICI
plus the antisense ODN at P , 0.001.
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The pS2 gene encodes an 84-amino acid, cystein-rich, secretary pro-
tein, which is widely expressed in estrogen-sensitive tissues (57). Its
expression in prostate cancer specimens has been shown to be asso-
ciated with premalignant changes and neuroendocrine differentiation
(65, 66).
Different variants of ER-a transcripts are often found to coexist
with the wild-type transcript in normal and malignant tissues (67, 68).
These variants, produced by alternative splicing, are whole exon
deletion variants that may have “outlaw functions.” In PC-3 cells, a
previous study has demonstrated the expression of an exon 4 deletion
variant (51). In the current study, we found an exon 2 deletion variant
in PC-3, BPH-1, and PrEC (Clontech) cells. Whether ER transcript
variants have functional or regulatory roles in prostatic cells is a topic
of future investigation.
Therapies for metastatic prostate cancers are limited. In addition to
androgen ablation therapies, estrogens/antiestrogens have been used,
singularly or in combination with other modalities, for treatment of
the disease. DES is an effective treatment therapy; however, its
estrogenicity induces significant adverse effects in patients and have
resulted in termination of its use (7). In contrast, TAM, a nonsteroidal
antiestrogen, is better tolerated but produces little objective responses
in multiple trials (8–12). With the discovery of ER-b as a new
estrogen signaling pathway and the availability of pure antiestrogen
such as ICIs (13), it becomes appropriate to address the issue of
whether pure antiestrogens could be considered in the treatment of
prostate cancer. In this study, we have compared the efficacy of two
estrogens (E2 and DES) an two antiestrogens (4OH-TAM and ICI) in
inhibiting cell growth in two androgen-refractory prostate cancer cell
lines, PC-3 cells that we found express both ER subtypes, and DU145
cells that express only ER-b. Past studies have shown that DES, when
given at high concentrations (10–30 mM range), exerts colchicine-like
action, inhibits tubulin assembly, and induces apoptosis in prostate
cancer cells (69, 70). Because the focus of the current study is to
elucidate receptor-mediated action of DES, we have chosen to use
concentrations not higher than 1026 M. Our results demonstrated all
four estrogenic/antiestrogenic compounds, at relatively low doses,
exerted antiproliferative effects on PC-3 cells, with antiestrogens
exhibiting greater potencies. Furthermore, competition experiments
showed that DES could reverse the effect of ICI, thus suggesting that
estrogens and antiestrogens may share similar cellular mediators in
this cell line. In contrast, DU145 cells responded only to antiestrogens
with regard to cell growth inhibition. In both cases, ICI was found to
be more potent than 4OH-TAM as a growth inhibitor. Furthermore,
competition experiments demonstrated that E2 did not reverse the
ICI-induced or 4OH-TAM-induced growth inhibition. This finding
suggests that estrogens have little impact on the antiestrogenic action
in DU145 cells. Importantly, the antiestrogen-induced growth-inhib-
itory response in DU145 cells was reversible by cotreatment with an
ER-b antisense ODN. Taken together, these findings raise several
significant implications: (a) it is apparent that the estrogen/antiestro-
gen-induced antiproliferative action on prostatic cancer cells is ER
subtype dependent. It supports the prediction for the antiproliferative
action of ER-b as previously discussed (71); (b) because ICI consis-
tently expresses a higher potency, it may be better suited to be used in
prostate cancer treatment. In clinical trails for breast cancer treatment,
this compound has demonstrated high efficacy and low toxicity (72);
and (c) our data have provided the first demonstration that estrogen/
antiestrogen action in prostatic cancer cells could signal via an ER-b
pathway. Because ER-b selective ligands have been reported recently
(73), this development raises the likelihood of using receptor subtype
ligands as cancer therapeutics in the future.
In summary, this study has demonstrated that human normal PrECs
express exclusively ER-b and likely signal via this receptor subtype
for estrogen/antiestrogen action. On the contrary, prostatic cancer
cells exhibit a more variable pattern of ER subtype expression, and
their responses to individual estrogen or antiestrogen will depend on
the ER subtype(s) expressed in the cells. Significantly, we provide the
first experimental evidence that ER-a gene silencing in prostate
cancer cells, and perhaps also in normal cells, may be caused by DNA
hypermethylation. Overall, data from this study lend support to the
notion that ER-b plays a central role in estrogen/antiestrogen signal-
ing in normal and malignant human PrECs.
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